Showing 2721-2730 of 4166 results for "".
- Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011https://modernod.com/news/aura-biosciences-reports-positive-phase-1b-2-clinical-data-for-au-011/2479713/Aura Biosciences has reported positive clinical data from its phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma. “Ocular melanoma is the most
- Staar Surgical Announces Agreement with Dr. Tobias Neuhann in Germany to Create Collaboration with Single Site Ophthalmology Clinicshttps://modernod.com/news/staar-surgical-announces-agreement-with-dr-tobias-neuhann-in-germany-to-create-collaboration-with-single-site-ophthalmology-clinics/2479798/Staar Surgical announced a multi-year strategic alliance agreement with Tobias Neuhann, MD, of the Augenklinik am Marienplatz (Eye Clinic at Marienplatz) in Munich, Germany. The agreement serves as a global partnership model for smaller and single site refractive surgery eye clinics that aim to p
- Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-results-from-phase-2b-dry-eye-disease-clinical-trial/2479841/Aldeyra Therapeutics announced positive results from its phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. “The early onset and broad activity observed in the phase 2b clinical trial sugg
- BioTime Further Expands OpRegen Clinical Trial in Dry AMD With the Opening of Two Additional US Siteshttps://modernod.com/news/biotime-further-expands-opregen-clinical-trial-in-dry-amd-with-the-opening-of-two-additional-us-sites/2480141/BioTime announced the expansion of its ongoing phase 1/2a clinical trial for OpRegen, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter. “The addition of these two leading U.S. clinical trial sites is in addition to our current two site
- ScienceBased Health Welcomes New Members to Its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-welcomes-new-members-to-its-optometry-clinical-advisory-panel/2481787/ScienceBased Health (SBH) announced the addition of Jaclyn Garlich, OD, FAAO; Jacob Lang, OD, FAAO, Dipl ABO; and Mark Schaeffer, OD to its Optometry Clinical Advisory Panel. ScienceBased Health develops and markets e
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical
- CXL Ophthalmics Appoints Jonathan H. Talamo, MD, to its Board of Managershttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-h-talamo-md-to-its-board-of-managers/2477675/CXL Ophthalmics announced the appointment of Jonathan H. Talamo, MD, to its Board of Managers. Dr. Talamo was most recently Chief Medical Officer and Worldwide Vice President of Clinical and Medical Affairs at Johnson and Johnson Vision. While at Johnson and Johnson Vision, Dr. Talamo hel
- Visionix Launches Optovue Solix FullRange OCThttps://modernod.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/Visionix USA has introduced the Optovue Solix FullRange OCT in North America. Featuring 120kHz ultra-high-speed scanning, Optovue Solix FullRange OCT features anterior 18 x 6.25 scans, new posterior high-density scan patterns for more detail and better precision, int
- eSight Assistive Device for Visually Impaired Available for Demonstrations at AAOhttps://modernod.com/news/esight-assistive-device-for-visually-impaired-available-for-demonstrations-at-aao/2481104/Vision enhancement platform,
- EssilorLuxottica to Acquire European Ophthalmology Network Optegra Clinicshttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmology-network-optegra-clinics/2482825/EssilorLuxottica and MidEuropa have entered into an agreement in which EssilorLuxottica will acquire Optegra, an integrated ophthalmology platform operating in five European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. Financial terms of the deal were